title: [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
abstract: Twenty females with disseminated breast cancer received courses of polychemotherapy with 21-day intervals. The regimen comprised adriamycin (ADM), cyclophosphamide and 5-fluorouracil in the dose 50, 500 mg/m2, respectively. 30 minutes prior to the treatment the patients were given the cardioprotector cardioxan (1000 mg/m2). Cardiological control (ECG, EF according to echo-CG and radionuclide ventriculography, PP/EP M1/M2, T1/T2 according to echo-polycardiography and Doppler cardiography) was performed before the treatment and at ADM total dose 200-300 mg/m2 followed by measurements at each dose increase by 100 mg/m2. The findings showed no evidence of ADM-related cardiac damage up to ADM dose 900-1000 mg/m2 in the case of cardioxan protection, though there was a tendency to M1/M2 increase which needs further studies as it suggests worsening of left ventricular diastolic contractility.
authors.forename: E D
authors.initials: ED
authors.lastname: Min'kov
authors.forename: G B
authors.initials: GB
authors.lastname: Niu-Tian-de
authors.forename: L V
authors.initials: LV
authors.lastname: Shkhvatsabaia
authors.forename: Iu B
authors.initials: IuB
authors.lastname: Bagdasarov
authors.forename: T I
authors.initials: TI
authors.lastname: Zaĭtseva
authors.forename: A A
authors.initials: AA
authors.lastname: Odzharova
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009202:Cardiomyopathies / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D011929:Razoxane / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D002317:Cardiovascular Agents; D011929:Razoxane; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil
vernacular_title: Otsenka kardioprotektivnogo deĭstviia preparata ICRF-187 (kardioksan) pri lechenii bol'nykh rakom molochnoĭ zhelezy bol'shimi dozami adriamitsina.